Abstract 4555
Background
DPX-Survivac is a novel T cell activating therapy that has been shown to elicit a strong and prolonged immune response against tumors expressing survivin and correlated with clinical benefits in ovarian cancer. The survivin specific T cells activated by DPX-Survivac, in combination with CPA, are infiltrating the tumors and lead to clinical responses. In preclinical studies, treatment with DPX-Survivac has shown to increase the PD-L1 and PD-1 expression. Pembrolizumab is a potent humanized IgG4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and 2 (PD-L2). This study investigates if a synergistic effect leading to enhanced clinical benefits for the subjects can be achieved with the combination of the checkpoint inhibitor pembrolizumab and the T cell activation therapy, DPX-Survivac, with CPA in subjects with solid tumors.
Methods
This basket trial recruits in ovarian cancer, HCC, NSCLC, bladder cancer and MSI-H tumors. Subjects from all cohorts receive DPX-Survivac and pembrolizumab with intermittent low dose CPA. Subjects are treated for up to 35 cycles of pembrolizumab or confirmed progression, whichever occurs first. The primary objectives are to determine the objective response rate (ORR) by RECIST 1.1 and the safety profile. Secondary objectives include duration of response, disease control rate, progression free survival (PFS), and overall survival (OS). Exploratory analyses will look at the T cell responses and infiltration of the tumor along with biomarker analysis.
Results
The lead-in safety assessment is complete with no modification to the dosing regimen. Preliminary data from the HCC, NSCLC, bladder cancer, and MSI-H cohorts are reported including ORR and safety as well as T cell responses and T cell infiltration.
Conclusions
No safety concerns have been observed with the combination therapy which is showing early signs of clinical efficacy. Enrollment is expected to continue to Stage 2 of the Simon 2 stage design.
Clinical trial identification
NCT03836352.
Editorial acknowledgement
Legal entity responsible for the study
IMV Inc.
Funding
IMV Inc.
Disclosure
L.D. MacDonald: Shareholder / Stockholder / Stock options, Full / Part-time employment: IMV Inc. S. Fiset: Shareholder / Stockholder / Stock options, Full / Part-time employment: IMV Inc. Y.M. Bramhecha: Shareholder / Stockholder / Stock options, Full / Part-time employment: IMV Inc. M. Chaney: Full / Part-time employment: Merck & Co. G.N. Rosu: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: IMV Inc. All other authors have declared no conflicts of interest.
Resources from the same session
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract
4758 - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster Display session 3
Resources:
Abstract